MarketCapExport financials
VistaGen Therapeutics (VTGN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
VistaGen Therapeutics VTGN
$ 0.26
0.21%
Facebook
X
Telegram
VistaGen Therapeutics Balance Sheet 2026-1999 | VTGN
Brief overview of VistaGen Therapeutics's financial position
The comparison uses five available annual reports from the 2022–2026 interval.
The asset base decreased -34.9%, from $74.6 million to $48.6 million. Resources became smaller over the five periods.
Liabilities expanded faster than the asset base, +31.4% versus -34.9%. Debt-service capacity deserves attention.
Internal capital represents 73.1% of the balance sheet, previously 86.7%. This is a strong capital position.
Net debt moved below zero to -$29.8 million, reflecting surplus cash over debt.
The cash reserve occupies 63.4% of the balance sheet, previously 91.3%. It is one marker of short-term resilience.
Retained earnings remain negative at -$477.3 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
VistaGen Therapeutics's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet VistaGen Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-29.8 M | -65.6 M | -117 M | -16.1 M | - | -99.4 M | 2.74 M | -13 M | -10.3 M | -2.85 M | -358 K | 14.2 M | 6.91 M | 4.7 M | 3.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt |
249 K | 948 K | 1.57 M | 7.4 K | - | 3.35 M | - | - | - | - | 27.2 K | 332 K | 4.78 M | 4.62 M | 2.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
699 K | 561 K | 550 K | 486 K | 433 K | 365 K | 313 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 4.44 M | 4.16 M | 12.1 M | 8.73 M | 4.14 M | 2.9 M | 1.73 M | 2.17 M | 3.42 M | 7.86 M | 11 M | 2.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
12.8 M | 12.6 M | 5.12 M | 4.57 M | 5.77 M | 4.19 M | 2.77 M | 2.8 M | 1.46 M | 1.37 M | 1.79 M | 17.4 M | 5.21 M | 2.41 M | 3.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
13 M | 14 M | 9.37 M | 9.01 M | 9.93 M | 16.3 M | 11.5 M | 6.94 M | 4.36 M | 3.1 M | 3.97 M | 20.8 M | 13.1 M | 13.4 M | 6.05 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.71 M | 2.59 M | 791 K | 714 K | 1.24 M | 1.42 M | - | - | - | - | - | - | - | - | 13.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-477 M | -408 M | -356 M | -327 M | -268 M | -220 M | -202 M | -181 M | -157 M | -142 M | -132 M | -84.5 M | - | - | -54.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
48.6 M | 84.3 M | 124 M | 21.1 M | 74.6 M | 108 M | 5.77 M | 14 M | 11.3 M | 3.71 M | 990 K | 270 K | 264 K | 882 K | 342 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
30.8 M | 67.1 M | 119 M | 16.6 M | 68.1 M | 103 M | 1.36 M | 13.1 M | 10.4 M | 2.92 M | 428 K | 70 K | - | 638 K | 81 K | 139 K | 201 K | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
35.5 M | 70.4 M | 114 M | 12.1 M | 64.7 M | 92 M | -5.73 M | 7.08 M | 6.92 M | 616 K | -2.98 M | -20.5 M | -12.8 M | -12.6 M | -5.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
35.5 M | 70.4 M | 114 M | 12.1 M | 64.7 M | 92 M | -5.73 M | 7.08 M | 6.92 M | 616 K | -2.98 M | -20.5 M | -12.8 M | -12.6 M | -5.71 M | -32.9 M | -26.3 M | -26.7 M | -22.2 M | -17.4 M | -16.5 M | -14.7 M | -13.7 M | -4.95 M | -4.58 M | -2.51 M | -844 K | -226 K |
All numbers in USD currency
Quarterly Balance Sheet VistaGen Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
431 K | 610 K | 783 K | 431 K | 610 K | 783 K | 1.42 M | 1.11 M | 1.27 M | 1.42 M | 7 K | 6 K | 6.5 K | 7 K | 7.4 K | 7.9 K | 8.3 K | 8.7 K | 2.61 M | 2.72 M | 3.14 M | 3.25 M | - | 3.45 M | 87.3 K | 125 K | 3 K | 3.8 M | 3.88 M | 3.96 M | 6.3 K | - | - | - | - | - | - | - | - | - | - | - | 27.2 K | 29.3 K | 31.4 K | 1.04 M | 35.6 K | 2.13 M | - | - | 1.8 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | 4.13 M | - | 3.64 M | 4.13 M | 4.44 M | 4.75 M | 5.05 M | 3.75 M | 4.16 M | 4.14 M | 11.9 M | 12 M | 12.1 M | 12.5 M | 12.7 M | 9.11 M | 8.73 M | 8.49 M | 8.25 M | 8.01 M | 4.14 M | 3.86 M | 3.59 M | 3.16 M | 2.9 M | 2.65 M | 2.4 M | 2.04 M | 1.73 M | 1.42 M | 1.14 M | 994 K | 2.17 M | 1.51 M | 909 K | 1.33 M | 3.42 M | 7.28 M | 10.9 M | 9.96 M | 7.86 M | 8.29 M | 9.91 M | 9.45 M | 7.86 M | 8.27 M | 3.94 M | 2.54 M | 11 M | 2.94 M | 3.07 M | 3.21 M | 7.85 M |
Total Liabilities |
14.1 M | 14.6 M | 12.2 M | 14.1 M | 14.6 M | 12.2 M | 8.74 M | 11.2 M | 9.52 M | 8.74 M | 8.18 M | 7.78 M | 6.55 M | 8.18 M | 9.01 M | 9.03 M | 11.1 M | 12.7 M | 9.93 M | 10.6 M | 19.8 M | 18.3 M | 16.3 M | 15.5 M | 16 M | 11.8 M | 11.5 M | 11.4 M | 12.4 M | 11.3 M | 6.94 M | 5.83 M | 4.9 M | 5.03 M | 4.36 M | 3.98 M | 4.29 M | 3.04 M | 3.1 M | 3.29 M | 2.94 M | 2.6 M | 3.97 M | 3.61 M | 3.26 M | 4.61 M | 20.8 M | 18 M | 17.8 M | 16.2 M | 13.1 M | 12 M | 13.2 M | 12.4 M | 13.1 M | 10.8 M | 6.88 M | 6.93 M | 13.4 M | 5.16 M | 9.26 M | 8.75 M | 18.7 M |
Deferred Revenue |
2 M | 2.14 M | 2.51 M | 2 M | 2.14 M | 2.51 M | 2.3 M | 2.51 M | 2.47 M | 2.3 M | 714 K | 1.76 M | 793 K | 714 K | 714 K | 712 K | 712 K | 1.24 M | 1.24 M | 1.42 M | 1.42 M | 1.42 M | 1.42 M | 1.24 M | 1.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-461 M | -442 M | -423 M | -461 M | -442 M | -423 M | -367 M | -394 M | -380 M | -367 M | -334 M | -347 M | -340 M | -334 M | -327 M | -315 M | -305 M | -287 M | -268 M | -251 M | -240 M | -228 M | -220 M | -214 M | -208 M | -205 M | -202 M | -199 M | -193 M | -187 M | -181 M | -175 M | -168 M | -161 M | -157 M | -152 M | -149 M | -144 M | -142 M | -139 M | -137 M | -134 M | -132 M | -123 M | -121 M | -114 M | -84.5 M | -78.3 M | -77.2 M | -75.2 M | -70.6 M | -68.8 M | -68.9 M | -67.5 M | -70.6 M | -63.9 M | -58.6 M | -56.6 M | -67.7 M | -51.7 M | -47.2 M | -45 M | -42.6 M |
Total Assets |
65.1 M | 80.9 M | 68.9 M | 65.1 M | 80.9 M | 68.9 M | 114 M | 92.3 M | 102 M | 114 M | 15 M | 131 M | 42.2 M | 15 M | 21.1 M | 29.7 M | 40.7 M | 58.7 M | 74.6 M | 90.5 M | 100 M | 104 M | 108 M | 109 M | 20.3 M | 6.17 M | 5.77 M | 5.33 M | 8.74 M | 12.9 M | 14 M | 7.52 M | 8.89 M | 8.26 M | 11.3 M | 14.2 M | 2.62 M | 2.44 M | 3.71 M | 5.88 M | 7.02 M | 8.76 M | 990 K | 2.01 M | 1.93 M | 1.74 M | 270 K | 259 K | 387 K | 765 K | 264 K | 329 K | 406 K | 432 K | 264 K | 326 K | 425 K | 645 K | 882 K | 400 K | 537 K | 1.68 M | 324 K |
Cash and Cash Equivalents |
47.4 M | 62.8 M | 49 M | 47.4 M | 62.8 M | 49 M | 103 M | 74.7 M | 84.2 M | 103 M | 9.62 M | 127 M | 37.6 M | 9.62 M | 16.6 M | 25 M | 35.3 M | 52 M | 68.1 M | 83.7 M | 93.6 M | 97.8 M | 103 M | 104 M | 15.4 M | 1.55 M | 1.55 M | 1.06 M | 1.06 M | 4.07 M | 8.3 M | 6.29 M | 6.29 M | 7.83 M | 10.4 M | 13 M | 1.76 M | 1.63 M | 2.92 M | 4.37 M | 6.26 M | 8.5 M | 428 K | 1.16 M | 694 K | 121 K | 70 K | 13.2 K | - | 401 K | - | 20.7 K | 6.5 K | 89.8 K | 638 K | 24.2 K | 13.4 K | 31.7 K | 81 K | 166 K | 94.5 K | 94.5 K | 139 K |
Book Value |
50.9 M | 66.3 M | 56.8 M | 50.9 M | 66.3 M | 56.8 M | 105 M | 81.1 M | 93 M | 105 M | 6.85 M | 123 M | 35.6 M | 6.85 M | 12.1 M | 20.7 M | 29.6 M | 46.1 M | 64.7 M | 80 M | 80.7 M | 85.6 M | 92 M | 93.8 M | 4.22 M | -5.61 M | -5.73 M | -6.09 M | -3.63 M | 1.63 M | 7.08 M | 1.69 M | 3.99 M | 3.22 M | 6.92 M | 10.3 M | -1.67 M | -607 K | 616 K | 2.59 M | 4.09 M | 6.16 M | -2.98 M | -1.6 M | -1.32 M | -2.87 M | -20.5 M | -17.8 M | -17.4 M | -15.4 M | -12.8 M | -11.7 M | -12.8 M | -11.9 M | -12.8 M | -10.5 M | -6.46 M | -6.28 M | -12.6 M | -4.76 M | -8.72 M | -7.07 M | -18.3 M |
Total Shareholders Equity |
50.9 M | 66.3 M | 56.8 M | 50.9 M | 66.3 M | 56.8 M | 105 M | 81.1 M | 93 M | 105 M | 6.85 M | 123 M | 35.6 M | 6.85 M | 12.1 M | 20.7 M | 29.6 M | 46.1 M | 64.7 M | 80 M | 80.7 M | 85.6 M | 92 M | 93.8 M | 93.8 M | 4.22 M | -5.61 M | -6.09 M | -6.09 M | -3.63 M | 1.63 M | 1.69 M | 1.69 M | 3.99 M | 6.92 M | 10.3 M | -1.67 M | -607 K | 616 K | 2.59 M | 4.09 M | 6.16 M | -2.98 M | -1.6 M | -1.32 M | -2.87 M | -20.5 M | -17.8 M | -17.4 M | -15.4 M | -12.8 M | -11.7 M | -12.8 M | -11.9 M | -12.6 M | -10.5 M | -6.46 M | -6.28 M | -5.71 M | -4.76 M | -8.72 M | -7.07 M | -32.9 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of VistaGen Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Agios Pharmaceuticals
AGIO
|
$ 31.25 | 0.88 % | $ 1.81 B |  USA |
 |
Foghorn Therapeutics
FHTX
|
$ 2.0 | 0.74 % | $ 126 M | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 2.0 | 0.5 % | $ 197 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.0 | 1.34 % | $ 461 M |  Israel |
 |
Intellia Therapeutics
NTLA
|
$ 12.75 | 4.0 % | $ 1.38 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 14.5 | 3.19 % | $ 1.43 B | USA |
 |
Viridian Therapeutics
VRDN
|
$ 19.0 | 2.16 % | $ 1.93 B | USA |
 |
AbbVie
ABBV
|
$ 265.76 | 1.12 % | $ 470 B | USA |
 |
AbCellera Biologics
ABCL
|
$ 13.78 | 0.29 % | $ 4.12 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
$ 5.11 | 1.59 % | $ 271 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.67 | 4.94 % | $ 895 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 20.11 | 0.8 % | $ 3.39 B | USA |
 |
Achieve Life Sciences
ACHV
|
$ 7.01 | 0.13 % | $ 306 M | USA |
 |
AC Immune SA
ACIU
|
$ 2.71 | 0.55 % | $ 273 M |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
$ 4.27 | 0.79 % | $ 523 M | USA |
 |
Adagene
ADAG
|
$ 2.8 | 0.28 % | $ 165 M |  China |
 |
ADC Therapeutics SA
ADCT
|
$ 1.23 | 8.85 % | $ 156 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
$ 4.35 | 5.58 % | $ 2.91 M | USA |
 |
ADMA Biologics
ADMA
|
$ 10.11 | 4.01 % | $ 2.41 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 29.84 | 5.26 % | $ 4.53 B | USA |
 |
Agenus
AGEN
|
$ 8.73 | 4.43 % | $ 260 M | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.19 | 5.56 % | $ 308 K | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.91 | 5.26 % | $ 234 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 8.76 | 0.46 % | $ 590 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.92 | 4.88 % | $ 55.3 M | USA |
 |
Alector
ALEC
|
$ 1.99 | 9.94 % | $ 205 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.4 | 0.36 % | $ 53.4 M | USA |
 |
Alkermes plc
ALKS
|
$ 42.76 | 2.42 % | $ 7.04 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.5 | 0.33 % | $ 331 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 219.89 | 0.08 % | $ 28.8 B | USA |
 |
Altimmune
ALT
|
$ 2.67 | 0.36 % | $ 235 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.21 | 1.23 % | $ 64.9 M | USA |
 |
Amgen
AMGN
|
$ 402.98 | 0.08 % | $ 217 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.37 | 0.39 % | $ 1.19 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 12.09 | 0.31 % | $ 5.02 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 20.35 | 0.25 % | $ 6.38 B | USA |
 |
AnaptysBio
ANAB
|
$ 49.2 | 1.38 % | $ 1.43 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 19.73 | 3.3 % | $ 283 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 72.58 | 0.55 % | $ 1.46 B | USA |
 |
Annexon
ANNX
|
$ 4.2 | 0.24 % | $ 651 M | USA |
 |
Annovis Bio
ANVS
|
$ 1.2 | 1.69 % | $ 24.7 M | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.68 | 0.16 % | $ 4.45 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.8 | 2.27 % | $ 568 K | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.57 | 0.44 % | $ 489 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 14.66 | 12.51 % | $ 401 M | Israel |
 |
Ardelyx
ARDX
|
$ 3.39 | 1.5 % | $ 817 M | USA |
 |
argenx SE
ARGX
|
$ 912.87 | 1.28 % | $ 56 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.66 | 3.98 % | $ 133 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 25.15 | 0.04 % | $ 3.2 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 3.51 | 0.54 % | $ 664 K | USA |